BioSpace News Archive

GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology testing, pathogen detection, and cancer research is pleased to announce an agreement with Roche to provide a highly multiplexed respiratory panel for wastewater surveillance on the new Roche Digital LightCycler® System.

BD announced it has been ranked in the top 10 for overall transparency and awarded Best Code of Conduct among S&P 250 companies in the fifth annual U.S. Transparency Awards by Labrador, a global communications firm specializing in corporate disclosures.

Baxter Planning today announced that Roche Diagnostics Corporation, the North American headquarters for Roche Diagnostics, selected Baxter Planning as a service optimization partner. Roche will be leveraging Baxter Planning’s Service Parts Management Platform, BaxterPredict, to maximize parts availability.

Gold Colloid, Co., a leading lateral flow assay development service company, announced today that it has acquired assets from Clip Health, Inc., a Covid-19 lateral flow manufacturing company.

Chronic kidney disease (CKD) is characterized by progressive irreversible loss of kidney function over time

The Institute for Myeloma & Bone Cancer Research (IMBCR) announces the publication in Targeted Oncology on the outstanding survival of 161 unselected, new patients with multiple myeloma (MM) who started treatment from 2006 to 2022 at Berenson Cancer Center.

Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September 28th in New York City.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel®) in the U.S.

Align Technology, Inc. shared highlights from the 2023 Invisalign GP Summit, the Company’s premier clinical education and networking experience designed to help doctors transform and grow their practice with Invisalign® clear aligners, iTero scanners, and the Align Digital Platform™.